Short answer
Spyre Therapeutics, Inc. (SYRE) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$36M
- +1.4% YoY · +47.5% QoQ
- EPS (diluted)
- −$0.35
- +67.9% YoY · +52.7% QoQ
Source: XBRL data from the Spyre Therapeutics, Inc. (SYRE) Q2 2026 10-Q on SEC EDGAR. USD.
Spyre Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New AI-related risk: expanding AI use exposes Spyre to operational, regulatory, legal, and ethical risks
- Capital requirement: $1,145.3 million cash, equivalents, and marketable securities at June 30, 2026, but continued operations require additional funding
- Financing dilution: April 2026 offering of 7,475,000 common shares generated approximately $463 million
- Regulatory risk: clinical programs may face delays from unresolved regulatory-authority interpretation of data sufficiency
- Competitive risk: safer, more effective, cheaper, or better-dosed competing products could reduce or eliminate commercial opportunity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Spyre Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.